By Dr Amarpreet S Dhiman In terms of drug discovery and development, the role of nanotechnology currently lies in improving diagnostic methods, developing improved drug formulations and drug delivery systems for disease therapy. The breakthrough format of nanotechnology offers innovative solutions, giving researchers greater… Read More
TR-FRET Based Assays – Getting better with age By Dr John Comley Despite having been available for nearly 15 years, TR-FRET based assays are still the preferred fluorescent assay format for many screeners. A recent survey ranked Cisbio’s TR-FRET product (HTRF) as the most frequently used generic… Read More
Share Share Tweet Email Understanding the strategic importance of BIOMARKERS for the discovery and early development phases Understanding the strategic importance of BIOMARKERS for the discovery and early development phases By Dr Orest Hurko… Read More
By Dr George G. Harrigan The potential of metabolomics, a systems approach to biochemical pathway analysis, to yield scientific and commercial benefits to healthcare and biotechnology enterprises is increasingly recognised. This article discusses current applications and future developments and places an emphasis… Read More
The Time is Right for Labs to Embrace the principles of Industrial Automation By John Dulchinos and Peter Massaro The pharmaceutical industry has never been a harbinger to change and modernisation, indeed, it is readily accepted that it is a good decade behind other industries in terms of… Read More
High Throughput Screening: meeting the challenges of more cell-based assays and HCS By Sandra Fox, MBA The use of high content screening and cell-based assays within high throughput screening (HTS) laboratories is on the increase but there are still many challenges to overcome. Read More
The Role of the Medicinal Chemist in the Drug Discovery Process: current status and future prospects By Dr Stevan W Djuric The need for the pharmaceutical industry to produce a constant stream of new NCEs has never been more paramount but with constantly changing R&D paradigms what is… Read More
Personalised Medicine: What’s in it for big pharma? By Dr Stephen Little There is nothing more difficult to take in hand, more perilous to conduct, or more uncertain in its success, than to take the lead in the introduction of a new order of things. Because the… Read More
Building a uHTS laboratory communications from the frontier By Dr Peter Hodder Through sheer commercial need to conduct HTS reliably, rapidly and economically, science and technology have partnered to move laboratories from semi-automated craft guilds to industrialised uHTS research operations. To the benefit of… Read More
Share Share Tweet Email Automated Patch Clamping: Setting a new standard for early hERG Automated Patch Clamping: Setting a new standard for early hERG By Dr John Comley Ion channel targets remain a top… Read More
Advances in the imaging of biomolecules: the label-free intrinsic imaging approach By Dr Stuart Hassard, Dr Anthony D. Baxter and Dr John Hassard Many stages in the process of drug discovery require the separation, identification and analysis of biomolecules such as proteins, peptides and nucleic acids. Such… Read More
New Options for Cell-Based Assay Automation By Dr John Comley The findings of a recent survey on cell-based assay automation revealed that no single factor stands out as the predominant reason productivity is limited in current cell-based automation. However, improving the quality of… Read More
Applying the semantic web to drug discovery and development By Dr Eric Neumann There is much happening in drug development these days: new target classes, increasing costs, new forms of high throughput screening, and the promise of personalised medicine. But of all the issues, the one that… Read More
High Content Screening – Emerging importance of novel reagents/probes and pathway analysis By Dr John Comley The number of high content screens will increase by 50% over the coming year; signal pathway analysis was seen as the most relevant high content screening (HCS) application; with greatest interest in… Read More
By Dr Y. Douglas Dolginow The art and science of prediction is a risky and humiliating exercise. As bad as we are at it, predicting things remains one of the fundamental human instincts, undoubtedly linked to a Darwinian selective advantage for our species. Read More
Ion Channels – New opportunities for an established therapeutic target class By Dr Andrew Southan, Iain F. James and David Cronk There is an increasing recognition within the pharmaceutical industry of the immense potential for ion channels as a drug target class. Advances in the understanding of… Read More